Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PSIX touches 3.00 - and with that wade size volume...
GEOS 12.61 (ask in afterhours) - lays a big egg...24M REV / (.32) EPS. Any guesses on how low it goes? I'll be looking for sub-$10 and only with a lucrative callwrite oppurtunity?
https://capedge.com/news/benzinga/38746140/geospace-technologies?fromCompany=1001115
IMMR - I also thought the numbers resembled scrambled eggs, and sold all my shares. The problem with stocks like this, and even moreso DBGI, is they set themselves up for that dreaded SEC investigation...and at that time it won't matter if they can prove legit, longterm, their pps WILL collapse in the immediate shortterm.
VNDA 5.06 - filed Q1 yesterday afternoon with following CC and the pps actually dipped? With this dip, VNDA is now my largest position in quite a while.
From the CC:
Mihael Polymeropoulos
...We expect several significant milestones in the coming months, including the launch of Fanapt in bipolar I disorder, the launch of PONVORY in multiple sclerosis, the potential approval of tradipitant in gastroparesis, the Phase III results of tradipitant in motion sickness, the upcoming NDA filings of milsaperidone in psychiatric disorders and tradipitant motion sickness and the initiation of clinical programs in depression, psoriasis, ulcerative colitis and pediatric insomnia.
We are confident that our robust revenue, strong cash position and efficient operations position us well for significant growth and value creation in the years to come...
https://capedge.com/transcript/1347178/2024Q1/VNDA
IMMR 7.32 - looked ready to bust-up yesterday and then faded. I also intend to hang on to my small position thru earnings, but this sure feels like a hot potato, yes?
PSIX 2.30 - adding...
Management Comments
Dino Xykis, Chief Executive Officer and Chief Technical Officer, commented, “Despite headwinds we experienced in the first quarter 2024, such as supply chain challenges from UFLPA and demand weakness on some products, the company managed to achieve profitability by prioritizing margin enhancement and efficient management of working capital. We expect sales will improve for the remaining year, driven by strong demand for our power systems products. We are also extremely pleased that we restored positive shareholder equity in the quarter, for the first time since 2020. We also paid down debt $5.0 million in the first quarter of 2024, and an additional $5.0 million in April 2024.”
Xykis continued, “While there will be challenges and uncertainties ahead of us in 2024, we are committed to profitable growth and expect growth from the power systems end market to help drive our outlook for the upcoming year.”
https://www.otcmarkets.com/filing/html?id=17518257&guid=yYQ-keaCFHLSJth#psiearningsrelease-march31_htm
VNDA - are they re-considering the proposal?
WASHINGTON, May 7, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC ("Future Pak") to acquire the Company. The revised proposal consists of a $7.25 to $7.75 per share in cash plus certain Contingent Value Rights ("CVRs"). The amended proposal follows Vanda's review and rejection of a prior unsolicited proposal from Future Pak to acquire the Company for $7.25-$7.75 per share.
Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, Vanda's Board of Directors will carefully review and evaluate the revised unsolicited proposal to determine the course of action that it believes is in the best interests of Vanda and its shareholders.
Vanda does not intend to comment further on the revised, unsolicited proposal before the Board has completed its review.
There is no action for shareholders to take at this time.
https://capedge.com/news/benzinga/38673993/vanda-pharmaceuticals?fromCompany=1347178
OMIC .445 - one of our prominent board-members frequently refers to "manipulation" in these markets...well I'm seeing a setup here where one might take advantage?
OMIC has until "July 15, 2024" to get the pps above $1.00 for 10 days...
On July 17, 2023, the Company received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). In response, the Company filed an application to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. As a result of the Approval, the Company has been granted an additional 180-day compliance period, or until July 15, 2024, to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company’s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day compliance period. If the Company fails to regain compliance during the additional compliance period, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company would have an opportunity to appeal the delisting determination to a Nasdaq Hearings Panel.
https://capedge.com/filing/1850906/0000950170-24-045597/OMIC-DEF14A
...or they intend to enact a R/S...so my risk without any "manipulation" (to a pps over a buck) will be to hold a $5 or $10 reverse-split stock still trading at approx. 1/3 of cash...
maxluke, I hadn't seen TSBX or IKNA...keep the newby nosedive cashfat-biobusts coming, thanks.. With all the recent biotech IPO's of the past few years, surely more will nosedive into lucrative oppurtunities.
I also continue to hold a sizeable position in OMIC and into a probable Reverse-Split which will certainly be advantageous to OMIC imo, altho I fully expect the madding crowd might take it the wrong way - lol.
XLO, AMLX, and VNDA are my fav's du jour...
especially VNDA @ 5.60 - approx. $7.00 BV, a $7 - $12 buyout offer on the table, a PDUFA date for "tradipant" on 9/18/24, Real Revenue/Minimal Burn, and very lucrative option premiums...and an announced Q1 filing after tomorrow's close which I fully expect them to re-hype all of the above.
VNDA 5.20 - Future Pak Increases Bid for Vanda Pharmaceuticals to Include CVRs in Addition to $7.25 to $7.75 Per Share in Cash
https://capedge.com/news/benzinga/38668822/future-pak-increases?fromCompany=1347178
RUN 11.90 - the May3rd, now expired, call-option-trade worked out nicely and I'll also now wait on the sidelines until after the earnings report. I also like ENPH...it's high on my solar watchlist...will very likely join you in ENPH with covered calls if the premiums remain lucrative.
I see the solar-sector as Can'tMiss longterm however shortterm it's in a deep rut for many reasons...
p.s. The Ameritrade option screen was my absolute go-to when trading options...I'll miss their option-screen moreso than any other facet of trading at ameritrade.
PSIX 2.15 - getting some Form-4 love from "Gagnon Securities"...
At Gagnon Securities, we pride ourselves on being different. Our investment premise is that the universe of lesser-known companies is largely inefficient. Companies can quietly dominate unrecognized niches and nimble innovators can be poised to thrive before they appear on the radar screens of the broader investment community. We employ a fundamental approach that seeks to identify and invest in companies that represent under-appreciated value.
https://www.gagnonsec.com/strategy
PSIX should be filing their Q1 report any day now...
RUN 10.02 - one of the badly beat-up solar sector stocks. Just bought at $10.02 and sold the $10May3rd call at .62. This transaction equates to roughly 20% per month...what I'm seeking?
Your "those who want to make 1000% return" equates to jibberish imho...
IMMR 7.15 - what's your take on this recent Barnes & Noble undertaking?
https://capedge.com/filing/1058811/0001213900-24-033529/IMMR-8K
I don't get it, neither the substance or the why?
GEOS 12.51 - got called out for a near perfect 'callwrite' trade...how often does that happen?
VNDA - the official version of the 'poison pill' has been posted...
https://capedge.com/filing/1347178/0001193125-24-099263/VNDA-8A12B
Is anyone able to make sense of this legalese mumbo jumbo? Ahhh, the promiscuity of the legal profession...
VNDA - here's an 8K 'poison pill' challenge for you:
Flip-In Trigger
If an Acquiring Person obtains beneficial ownership of 10% or more of the Common Stock, then each Right will entitle the holder thereof to purchase, for the Exercise Price, a number of shares of Common Stock (or, in certain circumstances, cash, property or other securities of the Company) having a then-current market value of twice the Exercise Price.
Following the occurrence of an event set forth in preceding paragraph, all Rights that are or, under certain circumstances specified in the Rights Agreement, were beneficially owned by an Acquiring Person or certain of its transferees will be void.
Flip-Over Trigger
If, after an Acquiring Person obtains 10% or more of the Common Stock, (1) the Company merges into another entity, (2) an acquiring entity merges into the Company or (3) the Company sells or transfers more than 50% of its assets, cash flow or earning power, then each Right (except for Rights that have previously been voided as set forth above) will entitle the holder thereof to purchase, for the Exercise Price, a number of shares of Common Stock of the person engaging in the transaction having a then-current market value of twice the Exercise Price.
https://capedge.com/filing/1347178/0001193125-24-099263/VNDA-8A12B
Why no "Flip-Out Trigger"? lol...and we watch
VNDA - officially rejected the offer soon after the announcement...I'm certain 'Future Pak' is legit.
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-confirms-rejection-of-unsolicited-takeover-proposals-from-future-pak-302119534.html
https://www.futurepak.com/
This stock has been very good to me for several months...already got one .45 flip this morning and this news would seem to secure my $4 callwrites...still flippin
VNDA 5.00 (premarket) - Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
https://finance.yahoo.com/news/future-pak-confirms-proposal-acquire-103000446.html
VNDA 5.00 (premarket) - Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
https://finance.yahoo.com/news/future-pak-confirms-proposal-acquire-103000446.html
ELYM - nice trading. I was holding out for a dip down to 2.60pps and never established a position...c'est la vie
OMIC .427 - also adding here. The PRE 14A is filed and assuming they follow through with a Reverse Split...we could well be holding a $5pps or $10pps stock trading at 1/4 of cash...it'd be a first for me.
3. To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect, at the option of our Board of Directors, a reverse stock split of our common stock at a ratio between 1-for-10 to 1-for-30, inclusive, as determined by our Board of Directors in its sole discretion. We refer to this as the “Reverse Stock Split Proposal” or “Proposal 3.”
https://capedge.com/filing/1850906/0000950170-24-042294/OMIC-PRE14A
CPSS 7.86 - adding on this morning's news...
Consumer Portfolio Services Appoints Gateway to Lead Expanded Investor Relations Program
https://ih.advfn.com/stock-market/NASDAQ/consumer-portfolio-servi-CPSS/stock-news/93600064/consumer-portfolio-services-appoints-gateway-to-le
With Book Value $13+ and current quarter EPS .29 maybe this recent development can help wake the madding crowd?
IMMR 7.20 - rebuying a little here...the chart looks right (how much control can Eric Singer really have?) and the successful lawsuit vs. META makes IMMR kinda special.
VNDA 4.88 - Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/93593630/vanda-pharmaceuticals-fanapt-iloperidone-receives
VNDA 4.88 - Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/93593630/vanda-pharmaceuticals-fanapt-iloperidone-receives
XLO 1.38 - nice buy. I exited my last shares yesterday before close and will attempt to swing trade the momentum, shortterm. Longterm, I thought the recent news was pretty dynamic for a $1 biotech stock and may try to build a poke to just hang on?
XLO 1.25 - interesting development announcing a corroboration with GILD, sizeable upfront payment, and more importantly this:
Item 8.01. Other Events.
As previously disclosed, in connection with Xilio Development, Inc., a wholly-owned subsidiary of Xilio Therapeutics, Inc. (the “Company”), entering into an exclusive license agreement with Gilead Sciences, Inc. (“Gilead”), on March 27, 2024, the Company entered into a stock purchase agreement with Gilead pursuant to which the Company agreed to, among other things, initially issue and sell 6,860,223 shares (the “Gilead Shares”) of its common stock, $0.0001 par value per share (the “Common Stock”), to Gilead in a private placement at a purchase price of $1.97 per share, for an aggregate purchase price of approximately $13.5 million (the “Initial Gilead Private Placement”). The Initial Gilead Private Placement closed on March 28, 2024.
As of March 25, 2024, the Company had 27,613,263 shares of Common Stock outstanding. Following the issuance of the Gilead Shares upon the closing of the Initial Gilead Private Placement on March 28, 2024, the Company had 34,473,486 shares of Common Stock outstanding.
https://www.sec.gov/edgar/browse/?CIK=1840233&owner=exclude
I'm still bidding 1.20's in afterhours as I'm 100% certain GILD knows more than I do concerning this specific matter.
XLO 1.25 - (clarification) 8K released afterhours:
Item 8.01. Other Events.
As previously disclosed, in connection with Xilio Development, Inc., a wholly-owned subsidiary of Xilio Therapeutics, Inc. (the “Company”), entering into an exclusive license agreement with Gilead Sciences, Inc. (“Gilead”), on March 27, 2024, the Company entered into a stock purchase agreement with Gilead pursuant to which the Company agreed to, among other things, initially issue and sell 6,860,223 shares (the “Gilead Shares”) of its common stock, $0.0001 par value per share (the “Common Stock”), to Gilead in a private placement at a purchase price of $1.97 per share, for an aggregate purchase price of approximately $13.5 million (the “Initial Gilead Private Placement”). The Initial Gilead Private Placement closed on March 28, 2024.
As of March 25, 2024, the Company had 27,613,263 shares of Common Stock outstanding. Following the issuance of the Gilead Shares upon the closing of the Initial Gilead Private Placement on March 28, 2024, the Company had 34,473,486 shares of Common Stock outstanding.
https://www.sec.gov/edgar/browse/?CIK=1840233&owner=exclude
I'm still bidding 1.20's in afterhours as I'm 100% certain GILD knows more than I do concerning this specific matter.
XLO - what's your opinion of this new GILD collaboration...any meat on the bone there? XLO still qualifies as a near-cash play. I might re-enter on any dip to 1.20's at the close in anticipation of a likely gap up in Monday's premarket.
VNDA 4.05 - just sold some April19/$4 calls at .40
PSIX 2.45 - finally getting some love...still too cheap!
https://www.nasdaq.com/market-activity/stocks/psix/revenue-eps
NKTX 9.87 - the April19-$10-Call Option is currently bidding at $1.10. Their recent K filing showed $5+ cash remaining and they just secondaried at $10 which should put them well above $5+ cash per share accompanied by some upcoming inevitable touting...one can only hope the option premiums remain this high?
https://finance.yahoo.com/news/nkarta-announces-pricing-240-million-103000060.html
New and existing investors participated in the offering, including Adage Capital Partners LP, Boxer Capital, Commodore Capital, Cormorant Asset Management, an affiliate of Deerfield Management, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, Ridgeback Capital Investments, Samsara BioCapital, SR One, and a leading mutual fund.
NKTX 9.87 - the April19-$10-Call Option is currently bidding at $1.10. Their recent K filing showed $5+ cash remaining and they just secondaried at $10 which should put them well above $5+ cash per share accompanied by some upcoming inevitable touting...one can only hope the option premiums remain this high?
https://finance.yahoo.com/news/nkarta-announces-pricing-240-million-103000060.html
New and existing investors participated in the offering, including Adage Capital Partners LP, Boxer Capital, Commodore Capital, Cormorant Asset Management, an affiliate of Deerfield Management, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, Ridgeback Capital Investments, Samsara BioCapital, SR One, and a leading mutual fund.
OMIC .51 - filed their Q4 yesterday. Kinda blah imo...increasing revenue however miles away from any profit, didn't provide guidance, and looks like they're committed to their plan (no close-the-doors-cashout for an easy triple).
Interesting development I see in OMIC's very near future. OMIC must respond to the “Minimum Bid Price Requirement” by July 15, 2024.The company has noted that if they can't meet the $1.00 threshold, they would entertain a Reverse Split. A possible WIN-WIN for a plebian shareholder?? We can be sure management will try every trick in the book to get the pps above $1.00...or...effect an R/S which should be a positive as the strong cash position would remain the same and a consequent higher pps would be much more attractive to investors?
As previously disclosed, on July 17, 2023, the Company received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). In response, the Company filed an application to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. As a result of the Approval, the Company has been granted an additional 180-day compliance period, or until July 15, 2024, to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company’s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day compliance period. If the Company fails to regain compliance during the additional compliance period, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company would have an opportunity to appeal the delisting determination to a Nasdaq Hearings Panel.
In connection with obtaining the Approval, the Company notified Nasdaq in writing of its intention to cure its deficiency in satisfying the Minimum Bid Price Requirement by effecting a reverse stock split prior to July 15, 2024, if necessary.
The Company intends to continue to actively monitor the Minimum Bid Price Requirement and, as appropriate, will consider available options to resolve any deficiencies and regain compliance.
https://capedge.com/filing/1850906/0000950170-24-005804/OMIC-8K
VNDA / GERN - I was going to respond with GERN is ripe for a secondary while VNDA is not...guess my brain was working too slowly? lol
My point was about the extreme high risk associated with GERN while so many biobusts such as VNDA are trading well below cash and also hold reward value while sustaining a very low risk.
ELYM - strange that they announce they're buying something but don't say what lol? Approx. $4 cash with a super clean Balance Sheet. I stuck in a low-ball order...will watch.
https://capedge.com/filing/1768446/0001193125-24-070333/ELYM-8K/file/2